This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ding, I. Articles by Min, W. Search for Related Content PubMed PubMed Citation Articles by Ding, I. Articles by Min, W.

Intratumoral Administration of Endostatin Plasmid Inhibits Vascular Growth and Perfusion in MCa-4 Murine Mammary Carcinomas¹

Departments of Radiation Oncology [I. D., J. Z. S., B. F., W. M. L., P. O.], Pediatrics [P. K.], and Medicine [W. M.], University of Rochester School of Medicine, Rochester, New York 14642

Endostatin, a fragment of the COOH-terminal domain of mouse collagen XVIII is a recently demonstrated endogenous inhibitor of tumor angiogenesis and endothelial cell growth. Antiangiogenic therapy with endostatin in animals requires multiple and prolonged administration of the protein. Gene therapy could provide an alternative approach to continuous local delivery of this antiangiogenic factor in vivo. Established MCa-4 murine mammary carcinomas, grown in immunodeficient mice, were treated with intratumoral injection of endostatin plasmid at 7-day intervals. At the time of sacrifice, 14 days after the first injection, endostatin-treated tumor weights were 51% of controls (P < 0.01). Tumor growth inhibition was accompanied by a marked reduction in total vascular density. Specifically, computerized image analysis showed a 18–21% increase in the median distances between tumor cells and both the nearest anatomical (CD31-stained) vessel [48.1 ± 3.8 versus 38.3 ± 1.6 µm (P < 0.05)] and the nearest tumor-specific (CD105-stained) vessel [48.5 ± 1.5 versus 39.8 ± 1.5 µm (P < 0.01)]. An increased apoptotic index of tumor cells in endostatin-treated tumors [3.2 ± 0.5% versus 1.9 ± 0.3% (P < 0.05)] was observed in conjunction with a significant decrease in tumor perfused vessels (DiOC₇ staining), and an increase in tumor cell hypoxia (EF5 staining). Hypoxia resulting from endostatin therapy most likely caused a compensatory increase of in situ vascular endothelial growth factor (VEGF) and VEGF receptor mRNA expression. Increased immunoreactivity of endostatin staining in endostatin-treated tumors was also associated with an increased thrombospondin-1 staining [1.12 ± 0.16 versus 2.44 ± 0.35]. Our data suggest that intratumoral delivery of the endostatin gene efficiently suppresses murine mammary carcinoma growth and support the potential utility of the endostatin gene for cancer therapy.

This article has been cited by other articles:

				C. Su, M. Na, J. Chen, X. Wang, Y. Liu, W. Wang, Q. Zhang, L. Li, J. Long, X. Liu, et al. Gene-Viral Cancer Therapy Using Dual-Regulated Oncolytic Adenovirus with Antiangiogenesis Gene for Increased Efficacy Mol. Cancer Res., April 1, 2008; 6(4): 568 - 575. [Abstract] [Full Text] [PDF]

				E. L. Coutinho, L. N. de Sousa Andrade, R. Chammas, L. Morganti, N. Schor, and M. H. Bellini Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma FASEB J, October 1, 2007; 21(12): 3153 - 3161. [Abstract] [Full Text] [PDF]

				R. Goel, D. Swanlund, J. Coad, G. F. Paciotti, and J. C. Bischof TNF-{alpha}-based accentuation in cryoinjury--dose, delivery, and response Mol. Cancer Ther., July 1, 2007; 6(7): 2039 - 2047. [Abstract] [Full Text] [PDF]

				X. Zhang, J. Xu, J. Lawler, E. Terwilliger, and S. Parangi Adeno-Associated Virus-Mediated Antiangiogenic Gene Therapy with Thrombospondin-1 Type 1 Repeats and Endostatin Clin. Cancer Res., July 1, 2007; 13(13): 3968 - 3976. [Abstract] [Full Text] [PDF]

				T. Noro, K. Miyake, N. Suzuki-Miyake, T. Igarashi, E. Uchida, T. Misawa, Y. Yamazaki, and T. Shimada Adeno-Associated Viral Vector-Mediated Expression of Endostatin Inhibits Tumor Growth and Metastasis in an Orthotropic Pancreatic Cancer Model in Hamsters Cancer Res., October 15, 2004; 64(20): 7486 - 7490. [Abstract] [Full Text] [PDF]

				Q. Zhang, M. Nie, J. Sham, C. Su, H. Xue, D. Chua, W. Wang, Z. Cui, Y. Liu, C. Liu, et al. Effective Gene-Viral Therapy for Telomerase-Positive Cancers by Selective Replicative-Competent Adenovirus Combining with Endostatin Gene Cancer Res., August 1, 2004; 64(15): 5390 - 5397. [Abstract] [Full Text] [PDF]

				J. P. Thomas, R. Z. Arzoomanian, D. Alberti, R. Marnocha, F. Lee, A. Friedl, K. Tutsch, A. Dresen, P. Geiger, J. Pluda, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors J. Clin. Oncol., January 15, 2003; 21(2): 223 - 231. [Abstract] [Full Text] [PDF]

				H. K. Kleinman and G. Liau Gene Therapy for Antiangiogenesis J Natl Cancer Inst, July 4, 2001; 93(13): 965 - 967. [Full Text] [PDF]

				S. Filleur, O. V. Volpert, A. Degeorges, C. Voland, F. Reiher, P. Clezardin, N. Bouck, and F. Cabon In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects Genes & Dev., June 1, 2001; 15(11): 1373 - 1382. [Abstract] [Full Text] [PDF]